Davidson Investment Advisors Raises Position in Zoetis Inc. $ZTS

Davidson Investment Advisors lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 107.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,868 shares of the company’s stock after acquiring an additional 58,044 shares during the quarter. Davidson Investment Advisors’ holdings in Zoetis were worth $8,039,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. purchased a new stake in Zoetis in the 2nd quarter valued at approximately $25,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at approximately $28,000. Finally, Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Up 3.2%

ZTS opened at $77.45 on Friday. The business’s fifty day moving average is $75.57 and its two-hundred day moving average is $95.62. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market cap of $32.00 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.80 and a beta of 0.74. Zoetis Inc. has a one year low of $71.00 and a one year high of $156.49.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of recent analyst reports. William Blair reissued a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. BNP Paribas Exane cut their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.